Literature DB >> 1191997

Observations on the systemic effect of topical clobetasol propionate (Dermovate).

J A Carruthers, P J August, R C Staughton.   

Abstract

Topical application of clobetasol propionate in a strength of 0-05% in cream or ointment (Dermovate) suppressed the hypothalamic-pituitary-adrenal axis in both normal people and patients with diseased skin. In normal people the 9 am serum cortisol level was suppressed when between 45 and 90 g was applied weekly. Insulin stress test results in patients with diseased skin showed an abnormally small response after long-term application of similar amounts. We conclude that long-term administration should be restricted to less than 50 g a week.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1191997      PMCID: PMC1674965          DOI: 10.1136/bmj.4.5990.203

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  Generalized pustular psoriasis on withdrawal of clobetasol propionate ointment.

Authors:  J D Boxley; R P Dawber; R Summerly
Journal:  Br Med J       Date:  1975-05-03

2.  THE ADRENOCORTICAL RESPONSE TO INSULIN-INDUCED HYPOGLYCAEMIA.

Authors:  J LANDON; V WYNN; V H JAMES
Journal:  J Endocrinol       Date:  1963-11       Impact factor: 4.286

3.  The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial.

Authors:  C G Sparkes; L Wilson
Journal:  Br J Dermatol       Date:  1974-02       Impact factor: 9.302

4.  Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases.

Authors:  H Baker; T J Ryan
Journal:  Br J Dermatol       Date:  1968-12       Impact factor: 9.302

5.  Pustular psoriasis with adrenal suppression following topical corticosteroids.

Authors:  R S Tan
Journal:  Proc R Soc Med       Date:  1974-08

6.  Letter: Adrenal unresponsiveness associated with clobetasol propionate.

Authors:  M Feiwel; W F Kelly
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

7.  Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay.

Authors:  B E Murphy
Journal:  J Clin Endocrinol Metab       Date:  1967-07       Impact factor: 5.958

8.  Letter: Adrenal suppression by clobetasol propionate.

Authors:  E Ortega; K H Burdick; E J Segre
Journal:  Lancet       Date:  1975-05-24       Impact factor: 79.321

9.  Cushing's syndrome and pituitary-adrenal suppression due to clobetasol propionate.

Authors:  R C Staughton; P J August
Journal:  Br Med J       Date:  1975-05-24
  9 in total
  13 in total

Review 1.  Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.

Authors:  Therdpong Tempark; Voraluk Phatarakijnirund; Susheera Chatproedprai; Suttipong Watcharasindhu; Vichit Supornsilchai; Siriwan Wananukul
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

Review 2.  Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids. A review.

Authors:  K L Goa
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  The use of Dermovate in the treatment of psoriasis.

Authors:  J A Carruthers
Journal:  Can Med Assoc J       Date:  1978-09-23       Impact factor: 8.262

Review 4.  Clinical use of topical cortisteroids.

Authors:  I B Sneddon
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 5.  Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Authors:  M Schäfer-Korting; M H Schmid; H C Korting
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

6.  Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands.

Authors:  Michiel W van der Linden; Fernie J A Penning-van Beest; Tamar Nijsten; Ron M C Herings
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Topical corticosteroids: clinical pharmacology and therapeutic use.

Authors:  J A Miller; D D Munro
Journal:  Drugs       Date:  1980-02       Impact factor: 9.546

8.  Epidermal thinning: evaluation of commercial corticosteroids.

Authors:  R Wrench
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

9.  Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs.

Authors:  Zifu Zhong; Séan McCafferty; Lisa Opsomer; Haixiu Wang; Hanne Huysmans; Joyca De Temmerman; Stefan Lienenklaus; João Paulo Portela Catani; Francis Combes; Niek N Sanders
Journal:  Mol Ther       Date:  2021-01-21       Impact factor: 11.454

10.  Emotional lability secondary to the application of a very potent topical corticosteroid.

Authors:  Srinivasa Sastry Malladi
Journal:  Indian J Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.